Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

Show simple item record

dc.contributor.author Denny, William en
dc.date.accessioned 2011-11-17T17:21:41Z en
dc.date.issued 2010-03 en
dc.identifier.citation Future Oncology 6(3):419-428 Mar 2010 en
dc.identifier.issn 1479-6694 en
dc.identifier.uri http://hdl.handle.net/2292/9243 en
dc.description.abstract The hypoxic cells common in solid tumors (because of their inefficient blood supply) limit the effectiveness of radiotherapy and many cytotoxic drugs. Nontoxic prodrugs that generate active species in hypoxic tissue by selective bioreduction have long been explored, and the first examples, representing a variety of different chemistries, have now reached advanced clinical trials. In the process, a great deal has been learnt about the properties that such drugs require to be successful, notably, efficient extravascular diffusion, appropriate reduction chemistry and kinetics, and an effective biological profile of the activated species, including a good bystander effect. The critical importance of prodrug diffusion and techniques to quantify this have assisted the development of models to predict the killing of tumor cells, which promises to help accelerate new drug evaluation. A cell cycleindependent mechanism of killing by the released cytotoxin is also a potential advantage, although it is likely that much of the killing will be when out-of-cycle hypoxic cells reoxygenate and resume division. en
dc.language EN en
dc.publisher Future Medicine Ltd. en
dc.relation.ispartofseries Future Oncology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1479-6694/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject banoxantrone (AQ4N) en
dc.subject bioreduction en
dc.subject cancer therapy en
dc.subject hypoxia-activated prodrug en
dc.subject PR-104 en
dc.subject TH-302 en
dc.subject tiropazamine en
dc.subject DNA CROSS-LINKING en
dc.subject II MARKER LESION en
dc.subject CELL LUNG-CANCER en
dc.subject N-OXIDE PRODRUG en
dc.subject TUMOR-CELLS en
dc.subject ANTITUMOR AGENTS en
dc.subject SOLID TUMORS en
dc.title Hypoxia-activated prodrugs in cancer therapy: progress to the clinic en
dc.type Journal Article en
dc.identifier.doi 10.2217/FON.10.1 en
pubs.issue 3 en
pubs.begin-page 419 en
pubs.volume 6 en
dc.rights.holder Copyright: Future Medicine Ltd. en
dc.identifier.pmid 20222798 en
pubs.end-page 428 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Review en
pubs.elements-id 119085 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Auckland Cancer Research en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2011-11-17 en
pubs.dimensions-id 20222798 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace